Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

Trial Identifier: D8455L00002
Sponsor: AstraZeneca
Start Date: April 2026
Primary Completion Date: November 2027
Study Completion Date: November 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China, Shanghai Shanghai, China